THE BI-0115 DIARIES

Hepatic impairment No dose adjustment is required in patients with moderate or average (Child-Pugh A or B) hepatic impairment (see segment five.two). Publicity to midostaurin and its Energetic metabolite CGP62221 is significantly reduce in individuals with extreme hepatic impairment than that in sufferers with usual hepatic perform (see segment 5.C